Sofia Alvarez MBA

CVRx Enrolls First Patient in BENEFIT-HF Heart Failure Trial Testing Barostim Device

CVRx begins landmark BENEFIT-HF clinical trial for Barostim neuromodulation device in expanded heart failure patient population at Avera Heart Hospital.

Vertex CASGEVY Gene Therapy Reaches 60,000+ Eligible Patients Across 10 Countries as Q1 2026 Results Show Global Expansion

Vertex's CASGEVY, the first approved CRISPR gene therapy, now serves 60,000+ eligible sickle cell disease and beta thalassemia patients across 10 countries.

Novelty Nobility Expands AGC Biologics Partnership for Bispecific Antibody Manufacturing

South Korean biotech Novelty Nobility expands manufacturing deal with AGC Biologics to advance bispecific antibody candidate through GMP production in Japan.

Smartee Denti-Technology Advances Mandibular Repositioning Technology at European Aligner Society Congress 2026

Smartee Denti-Technology presents breakthrough mandibular repositioning innovations and European expansion strategy at EAS Congress 2026 in Brussels.

FDA Approves Auvelity for MDD: Axsome Therapeutics' New Antidepressant

The FDA has approved Auvelity (dextromethorphan and bupropion) from Axsome Therapeutics for the treatment of major depressive disorder (MDD) in adults. This marks a significant advancement in MDD therapy with a new mechanism of action.

SynbioTech Unveils Microbiome-Based Platform for Women's Healthy Aging at Vitafoods Europe 2026

Taiwan-based SynbioTech presents clinical evidence for probiotic solutions targeting women's muscle maintenance, gut health, and metabolic balance at Vitafoods.

SetPoint Medical Begins Multiple Sclerosis Trial for Setpoint System Neuroimmune Therapy

SetPoint Medical enrolls first patients in pilot study testing Setpoint System for relapsing-remitting multiple sclerosis treatment with FDA approval.

Henlius and Organon's POHERDY Becomes First Pertuzumab Biosimilar Approved in Europe

European Commission approves POHERDY as first pertuzumab biosimilar in Europe, offering cost-effective alternative to PERJETA for breast cancer treatment.

Real-World Evidence Oncology Drugs: EMA vs MHRA Regulatory Approaches

This article compares the EMA and MHRA's regulatory frameworks for real-world evidence in oncology drugs, focusing on their implications for cancer treatment.

Brii Bio's Elebsiran Shows Durable Hepatitis B Control in APASL 2026 Cross-Study Analysis

Brii Bio's elebsiran combined with pegylated interferon demonstrates sustained HBsAg loss and favorable off-treatment outcomes in hepatitis B patients.

CAR-T Cell Therapy Japan: Regulatory Insights & Clinical Trial Landscape

This article delves into CAR-T cell therapy in Japan, highlighting regulatory frameworks and the evolving clinical trial landscape for hematologic malignancies.

EMA Issues Positive Opinion for Viatris' Palbociclib Generic Cancer Treatment

European Medicines Agency issues positive opinion for Viatris' generic palbociclib, potentially expanding access to this important breast cancer treatment.

Aetna Standardizes 88% of Prior Authorization Volume, Exceeds Industry Commitments for Healthcare Access

Aetna announces 88% prior authorization standardization, surpassing industry goals while maintaining fewest medical service requirements among national health plans.

RNA Therapy Clinical Trials Market Reaches $3.4 Billion as Personalized Medicine Drives Growth Through 2035

RNA therapy clinical trials market hits $3.4B driven by delivery advances, rare disease funding, and personalized medicine growth through 2035.

Center for Cancer and Blood Disorders Launches CAR T-Cell Therapy Program in Maryland, Expanding Community Access

CCBD becomes first Maryland community oncology practice to offer FDA-approved CAR T-cell therapy, significantly expanding patient access in the region.

Alpha Tau Treats First European Pancreatic Cancer Patient with Alpha DaRT in ACAPELLA Clinical Trial

Alpha Tau successfully treats first European patient with Alpha DaRT radiotherapy in French ACAPELLA trial for locally advanced pancreatic cancer.

Mauna Kea Technologies Secures CE Mark Under New MDR, Expands European Medical Device Approvals

Mauna Kea Technologies obtains CE Mark under new Medical Device Regulation and regulatory approvals in UK and Switzerland, marking significant expansion.

Ipsen Receives EU Approval for Ojemda (Tovorafenib) to Treat Pediatric Brain Cancer with BRAF Mutations

Ipsen secures conditional EU marketing authorization for Ojemda (tovorafenib) to treat pediatric low-grade glioma with BRAF alterations in patients 6 months and older.

Pediatric Clinical Trials: FDA's Updated Requirements and Incentives

This article discusses the FDA's latest updates on pediatric clinical trial requirements and incentives, emphasizing the importance of drug safety and efficacy for children.

RedHill's Opaganib Shows Promise in Neuroblastoma and Triple-Negative Breast Cancer Studies at AACR 2026

RedHill's opaganib demonstrates enhanced efficacy in neuroblastoma chemotherapy combinations and improved anti-tumor immunity in preclinical cancer studies.

Lung Cancer Therapeutics Market to Hit $142.3 Billion by 2036 as Precision Medicine Drives 11.8% Growth

Global lung cancer therapeutics market projected to grow from $46.8B to $142.3B by 2036, driven by precision medicine and immunotherapy advances.

Drug Delivery Devices Market Poised for Significant Growth Through 2032 Driven by Biologics and Regulatory Support

Drug delivery devices market shows strong growth potential through 2032, fueled by increasing biologics use, technological advances, and supportive regulations.